title: India's rejection of Novartis's patent is but a small step in the right direction.
authors.affiliation: soumyadeepbhaumik@rediffmail.com
authors.forename: Soumyadeep
authors.initials: S
authors.lastname: Bhaumik
mesh_terms: D000970:Antineoplastic Agents; D001549:Benzamides; D055808:Drug Discovery; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic; D006801:Humans; D000068877:Imatinib Mesylate; D007194:India; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010879:Piperazines; D011203:Poverty; D011743:Pyrimidines
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016568:Drugs, Generic; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate